#SHKelkar Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore

3. Gross margins in 9M FY22 stood at 41.4%

4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
6. The Company saw cost pressures on account of global inflation in raw materials and supply chain constraints, which impacted margin performance during the period.
In order to efficiently mitigate cost pressures, SHK is collaboratively working across customer segments and has been undertaking price hikes

7. Unless the debt is brought down to 2x of EBITDA, company will not look in for further acquisitions
8. CFF & Nova delivered growth on the back of stable demand and volume off-take in the Italian and European markets

9. With undertaking current acquisitions, net debt is expected around 550Cr in coming quarter
10. Cost of debt is between 3-3.5%

11. Target to maintain ROCE above 20%
Segment performance

Fragrance Division

1. The Fragrance division delivered a stable performance during Q3 & 9M FY22 despite raw material disruptions in the industry
2. Client wins across geographies continue to remain healthy

3. 91% of revenue i.e.360.7 Cr was contributed by fragrance division

4. EBITDA margins in the segment contracted by 100bps on YoY basis, margins stood at 14.2%
Region wise contribution

India- 55%, Europe- 26% and RoW- 19%

Domestic fragrance revenue grew by 11.6% YoY
Flavours Division

Margins were impacted on account of the raw material inflation
9% of revenue i.e.35.9 Cr was contributed by flavours division
EBITDA margins stood at 11.1% in Q3FY22 as against 11.3% in Q3FY21
Region wise contribution

India- 41%, Europe- 1% and RoW- 59%

Domestic flavours business grew by 3.8% whereas Europe contracted by 81.3% on YoY basis
New Acquisitions - Holland Aromatics

1. 62% of the stake has been acquired upon closure of the transaction on January 25, 2022 and the balance 38% shall be acquired in two tranches of 19% stake each over the next two years
2. The consideration for the acquisition of 62% stake is Euros 13.02 million. SHK funded the investment through local debt raised in Europe in order to avail the benefit of lower interest costs
3. The acquisition of Holland Aromatic will help to access and strengthen the client portfolio in the Indonesia region.

NuTaste Food and Drink Labs Pvt. Ltd.
SHK acquired a 100% stake at a total consideration of Rs. 13.25 crore.
SHK funded the investment through a combination of debt and internal accruals

4. The acquisition will accelerates the momentum of SHK’s flavour business and further brings on-board a solid and reputed customer base across the fast-growing FMCG & QSR space
5. The NuTaste is into chocolate, bakery and confectionery flavours, which will help in offering complimentary basket of products in concentrates and ready to use flavours to FMCG companies and nutrition supplements and flavours for beverages, pharmaceutical and bakery industry
Participation in Global RFPs

1. SHK is participating in a global RFP (Request for Proposal) and will engage with MNCs on an interactive pitch for commercial tender submission
2. Such global tender participation is in line with the Company’s strategy of more deeply associating with large global MNCs

3. The global RPF tender is what the company is looking forward and expects 5-7% value of the tender to be reflected in business

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 11
#SRF Q3 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translating growth of 55.9% YoY

2. EBITDA margins stood at 25.7%
Revenue breakup

Chemical business-42.6%, Packaging films-38.1%, Technical textile- 16.1% and others-3.2%
Business Highlights

1. Launched new pharma intermediate during the quarter and successfully conducted campaigns for 2-3 upcoming products.

2. Achieved highest ever production in key products and are constantly enhancing capacity utilisation at newly commissioned facility
Read 16 tweets
Feb 11
#Aartiindustries Q3 concall highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY

2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
Read 18 tweets
Feb 11
#AurobindoPharma Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).

4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
Read 18 tweets
Feb 11
#HesterBiosciences Q3 FY22 concall highlights 🐓🐓

Like & Retweet for better reach !

1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.

3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.
Read 14 tweets
Feb 11
#AlembicPharma Q3 FY22 concall highlights

Like & Retweet for better reach !

1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).

2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
3. PAT stood at 176 Cr (40% decline YoY).

4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
5. They have a couple of first-to-file launches coming up in FY23.

6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
Read 11 tweets
Feb 10
#GmmPfaudler Q3 2022 Concall Highlights

Like & Retweet for better reach

Operational Highlights

1. Revenues for Q3FY22 stood at ₹209 Cr from ₹166 Cr in same quarter previous year translating the growth of 26% YoY
2. EBITDA stood at ₹38 Cr with EBITDA margins at 18.1%

Operational Highlights :

1. Order intake in international business continues to remain strong with an increase of around 46% for nine months.
Order intake in India business continues to remain strong with an increase of around 39% for nine months

2. Higher input cost and investment in our new facilities, which are basically Vatva, and Hyderabad has impacted profitability in this quarter
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(